How many insider trades does FilingIQ track for VTGN?

FilingIQ tracks 110 Form 4 insider transactions for VTGN (Vistagen Therapeutics, Inc.), covering filings from Jun 19, 2016 onwards. 8 of those were filed in the last 90 days.

Are VTGN insiders net buyers or net sellers?

Across the full Form 4 history for VTGN, 10 transactions (9%) were open-market purchases and 2 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does VTGN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is VTGN in?

Vistagen Therapeutics, Inc. (VTGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $22.58M.

VTGN insider trading

NasdaqCM Healthcare

Vistagen Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

110

Last 90 days

Buys / sells

9% / 2%

Market cap

$22.58M

About Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Company website: www.vistagen.com

VTGN insider activity at a glance

FilingIQ has scored 110 insider transactions for VTGN since Jun 19, 2016. The most recent filing in our index is dated Apr 7, 2026.

Across the full history, 10 open-market purchases and 2 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on VTGN insider trades is 62.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live VTGN trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding VTGN

STEMPOINT CAPITAL LP

$4.29M · 1.3% of AUM

Frequently asked

How many insider trades does FilingIQ track for VTGN?: FilingIQ tracks 110 Form 4 insider transactions for VTGN (Vistagen Therapeutics, Inc.), covering filings from Jun 19, 2016 onwards. 8 of those were filed in the last 90 days.
Are VTGN insiders net buyers or net sellers?: Across the full Form 4 history for VTGN, 10 transactions (9%) were open-market purchases and 2 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does VTGN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is VTGN in?: Vistagen Therapeutics, Inc. (VTGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $22.58M.

Methodology & sources

Every VTGN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.